0001209191-24-000812.txt : 20240104 0001209191-24-000812.hdr.sgml : 20240104 20240104164351 ACCESSION NUMBER: 0001209191-24-000812 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wilson Marc CENTRAL INDEX KEY: 0001702265 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 24512739 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-02 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001702265 Wilson Marc C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 0 1 0 0 CFO 1 Common Stock 2024-01-02 4 M 0 10000 9.28 A 106055 D Common Stock 2024-01-02 4 S 0 10000 35.47 D 96055 D Non-qualified stock option (Right to Buy) 9.28 2024-01-02 4 M 0 10000 0.00 D 2028-05-24 Common Stock 10000 51185 D Includes 454 shares acquired under the Issuer's Employee Stock Purchase. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan. The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.47 per share. The range of sales prices on the transaction date was $34.41 to $36.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Marc Wilson 2024-01-04